PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia
B. M. Smith, J. VanCampen, G. L. Kong, W. Yashar, Y. H. Tsang, W. Horton, D. J. Coleman, J. Estabrook, T. A. Lusardi, G. B. Mills, B. J. Druker, J. E. Maxson, T. P. Braun
This paper shows that combining KIT and LSD1 inhibitors synergistically kills KIT-mutant AML cells by reducing MYC expression and inactivating PI3K/AKT signaling, supporting a clinical trial.
bioRxiv · Aug 24, 2021 · PreprintCancer Biology